New combo aims to keep leukemia from coming back after transplant
NCT ID NCT07199855
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether giving two drugs—blinatumomab and venetoclax—after a stem cell transplant can prevent relapse in adults with high-risk B-cell acute lymphoblastic leukemia (B-ALL). The study enrolls 24 people aged 14 to 65. The main goal is to see how many stay cancer-free for two years after transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- blinatumomab and venetoclax
- What this could lead to
- If successful, this combination could help prevent leukemia from returning after a stem cell transplant, improving long-term survival for high-risk patients.
- What could go wrong
- This is a small, early-phase study with only 24 participants, so results may not apply to everyone. The drugs can cause serious side effects like infections or nerve problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.